Which Companies Are Working on Brain-Computer Interfaces?

Brain-computer interfaces are moving from research laboratories into clinical trials and real-world applications. These systems record brain activity, interpret neural signals, and translate them into commands for computers, communication tools, or assistive devices.

Companies such as Neuralink, Synchron, Precision Neuroscience, Paradromics, and Blackrock Neurotech are developing physical connections between the human brain and technology. At the same time, another form of digital brain is emerging inside businesses. Growy applies a similar principle to company knowledge by connecting information, tools, processes, and AI agents through its company brain software.

The technologies serve different purposes. A brain-computer interface helps a person interact with a device through neural activity. Growy gives an entire organization a shared intelligence layer that employees and AI agents can use to find information and perform work.

Understanding this distinction makes it easier to explore the companies shaping both sides of the broader intelligence-interface market.

What is a brain-computer interface?

A brain-computer interface, commonly called a BCI, creates a direct communication channel between brain activity and an external device.

A typical BCI performs three operations:

1. Sensors record neural activity.
2. Software identifies meaningful patterns within those signals.
3. The decoded information is converted into an action or digital output.

For someone living with paralysis, that output might move a computer cursor, select letters on a screen, control a robotic arm, or generate synthetic speech.

Brain-computer interfaces can be divided into three broad categories.

Invasive brain-computer interfaces

Invasive systems place electrodes directly inside brain tissue. Their proximity to individual neurons can provide detailed signals and support precise control. Implantation, however, requires neurosurgery and creates significant safety, durability, and regulatory challenges.

Minimally invasive brain-computer interfaces

Minimally invasive systems position sensors on the brain’s surface or inside nearby blood vessels. Developers are attempting to preserve useful signal quality while reducing the complexity and risks of surgery.

Non-invasive brain-computer interfaces

Non-invasive systems measure brain activity from outside the skull, often through electroencephalography, or EEG. They are easier to use and do not require surgery, but the signals are generally less detailed than those obtained from implanted electrodes.

Neuralink

Neuralink is the most widely recognized company working on brain-computer interfaces.

Founded in 2016, the company is developing the N1 Implant, a fully implantable and wireless device designed to record neural activity. A surgical robot inserts flexible electrode threads into targeted areas of the brain. The system then transmits neural data to software that decodes the user’s intended movements.

Neuralink’s current clinical work focuses on people with severe paralysis. Its studies are examining whether participants can control computers and robotic arms through thought alone. The company is also developing technology intended to restore communication for people with speech disorders.

The immediate objective is medical: helping people with neurological conditions regain greater independence. Neuralink’s broader vision includes more general connections between human intelligence and computing, but these applications remain much further from clinical or commercial availability.

Synchron

Synchron is developing an implantable BCI called the Stentrode.

Unlike systems that require electrodes to be inserted directly into brain tissue, the Stentrode is delivered through the jugular vein. It is positioned inside a blood vessel near the motor cortex, where it records signals associated with the intention to move.

These signals can be converted into digital commands, allowing a user to perform activities such as browsing the web, writing messages, or interacting with connected devices.

The endovascular method is one of Synchron’s main differentiators. It avoids open brain surgery and may offer a more scalable implantation procedure than intracortical systems.

Synchron has conducted clinical research involving people with paralysis in the United States and Australia. Its system remains investigational and is not currently approved for general commercial use.

Precision Neuroscience

Precision Neuroscience is developing a thin electrode array called the Layer 7 Cortical Interface.

The device is designed to rest on the surface of the brain rather than penetrate deeply into brain tissue. It can be positioned through a narrow opening in the skull, allowing the system to collect high-resolution neural signals through a minimally invasive procedure.

Precision aims to help people with neurological conditions communicate and control digital devices. Its technology may also support neural monitoring during surgical procedures.

The company has received regulatory clearance for temporary clinical use of a high-resolution cortical electrode array. Its complete brain-computer interface remains an investigational technology.

Precision’s approach addresses one of the central challenges in the BCI industry: obtaining detailed neural data without introducing the risks associated with electrodes inserted further into the brain.

Paradromics

Paradromics is developing a high-bandwidth implantable BCI platform.

Its Connexus system uses arrays of small electrodes to record activity from individual neurons. The initial clinical objective is to restore communication for people who have lost the ability to speak.

Neural signals associated with intended speech could be decoded and converted into text or synthesized voice. This could allow people with severe paralysis or neurological disease to communicate more quickly than with conventional assistive devices.

Paradromics is also developing Tempo, a future system intended for active users and a wider range of neurological applications. Possible use cases include computer control, prosthetic control, speech restoration, and continuous monitoring of brain states.

The company’s technology remains focused on clinical development, with safety, signal quality, durability, and communication performance as its main priorities.

Blackrock Neurotech

Blackrock Neurotech is one of the most established companies in the BCI industry.

Its implanted neural-recording technology has been used in human research for many years. Participants using Blackrock systems have controlled robotic arms, operated computers, typed messages, and interacted with software through decoded brain activity.

The company develops electrode arrays, signal-processing equipment, and complete platforms for neural engineering research. Its technology has supported several important academic and clinical BCI programs.

Blackrock’s history gives it an advantage in the amount of human research conducted with its systems. While newer companies are beginning early clinical trials, Blackrock technology has already contributed to long-term studies involving people with paralysis.

Its challenge is turning complex research equipment into reliable systems that patients can use independently in their everyday lives.

Science Corporation

Science Corporation is a clinical-stage medical technology company working on several forms of neural interface.

One of its most advanced projects is PRIMA, a retinal implant developed to restore a form of central vision for people affected by geographic atrophy. The company is also researching biohybrid interfaces that use living neurons to create a connection between electronics and the brain.

This approach differs significantly from conventional electrode systems. Instead of relying entirely on wires or synthetic materials to interact with the brain, Science is investigating whether engineered living neurons can form a more stable and higher-bandwidth bridge.

The company also develops hardware and software components that other researchers can use to build neural-interface applications. Its work therefore extends from individual medical products to a broader BCI development ecosystem.

EMOTIV

EMOTIV develops non-invasive EEG headsets and brain-data software.

Its devices are worn on the head and use external sensors to record electrical activity. This makes the technology more accessible than an implanted system and suitable for research, education, accessibility, wellness, and experimental digital control.

Developers can use EMOTIV’s platform to translate selected patterns of brain activity into digital commands. Researchers also use the company’s products to study attention, mental workload, cognitive performance, and emotional responses.

Non-invasive EEG generally provides less precise information than implanted electrodes. However, it offers lower risk, lower cost, and greater accessibility. These advantages make it useful for developing and testing BCI applications outside clinical environments.

Kernel

Kernel develops non-invasive brain-imaging systems rather than a conventional implant for controlling devices.

Its Flow platform measures changes in brain activity using optical technology. The resulting data can support research into cognition, mental health, neurological conditions, and human performance.

Kernel is exploring how high-density brain data can be combined with artificial intelligence to identify patterns that may be difficult to observe through traditional clinical assessments.

The company’s current focus is therefore closer to brain measurement and analysis than direct computer control. Even so, its technology contributes to the wider BCI ecosystem by making neural data available for research and AI-powered interpretation.

Other companies working on BCI technology

The brain-computer interface market extends beyond the most visible companies. Several other businesses are exploring specialized applications and technical approaches.

Neurosoft Bioelectronics

Neurosoft develops flexible neural implants made from soft materials. Its goal is to reduce the mechanical mismatch between rigid electronics and delicate brain tissue.

The company is exploring minimally invasive systems for neurological conditions such as epilepsy and tinnitus.

Cognixion

Cognixion develops communication technology combining non-invasive brain sensing, augmented reality, and artificial intelligence.

Its work is particularly relevant to people with severe motor and communication impairments who may struggle to use traditional input devices.

INBRAIN Neuroelectronics

INBRAIN is developing graphene-based neural interfaces. Graphene may allow the creation of smaller and more sensitive electrodes for recording and stimulating brain activity.

The company is exploring applications involving neurological disorders and personalized neural treatments.

OpenBCI

OpenBCI provides open-source hardware and software for biosensing and BCI experimentation.

Its tools are used by researchers, developers, artists, and educational institutions. The open ecosystem makes it easier to prototype brain-controlled applications without developing every hardware component from scratch.

Neurable

Neurable develops non-invasive brain-sensing technology for consumer products, including headphones.

Its systems are intended to interpret signals related to attention, focus, and cognitive states. This approach could bring elements of neurotechnology into everyday devices without requiring specialist equipment.

How does Growy differ from a brain-computer interface?

Growy does not read neural activity or connect to a biological brain. It creates a digital brain for an organization.

Businesses already produce large amounts of knowledge, but that information is usually fragmented across:

• Shared documents
• Slack conversations
• CRM platforms
• Project management tools
• Standard operating procedures
• Customer support systems
• Meeting notes
• Internal databases
• Business applications
• The memory of individual employees

 

This fragmentation creates operational problems. Employees spend time searching for answers, teams follow different versions of a process, and important knowledge can disappear when someone leaves the company.

Growy connects these sources and turns them into an accessible company knowledge layer. Employees can ask questions in natural language and retrieve relevant answers based on the organization’s own information.

The platform can also provide company context to AI agents. Instead of operating with only general model knowledge, an agent can use approved policies, customer information, processes, previous decisions, and business rules.

This makes several applications possible:

• Enterprise search across connected company tools
• Centralized knowledge management
• Faster access to internal answers
• Creation and management of SOPs
• Customer and project context retrieval
• Automation of repetitive processes
• Support for operational AI agents
• Preservation of institutional knowledge
• More consistent decisions across teams

 

A physical BCI connects neural signals with a machine. Growy connects the collective intelligence of a company with the people and AI systems that need it.

Why are AI agents important to a company brain?

AI agents can perform more complex work than a traditional chatbot. They can retrieve information, follow a process, use connected tools, and complete approved actions.

Their usefulness depends on context. An agent cannot reliably handle an internal business task if it does not understand the company’s policies, terminology, customers, and workflows.

Growy supplies this missing context by connecting enterprise knowledge to AI-powered processes.

For example, an agent could:

• Find the correct procedure for a customer request
• Gather account information before a meeting
• Prepare a project summary from several sources
• Identify which business rule applies to a situation
• Draft a response using approved documentation
• Update a connected application
• Route a request to the correct person
• Monitor the completion of a recurring process

 

The company brain gives the agent the information it needs, while workflow rules define what it may do with that information.

Which BCI companies have implanted devices in humans?

Several companies have already used their technologies in people, although the maturity and purpose of their programs differ.

Neuralink has implanted its investigational system through clinical studies involving people with paralysis. Synchron has tested the Stentrode in patients in the United States and Australia. Blackrock Neurotech devices have been used in human neural-interface research for many years.

Precision Neuroscience has deployed surface electrode arrays in clinical settings. Science Corporation has advanced its retinal-interface technology through clinical development and into commercial use in Europe.

A device being implanted in a person does not mean it is available to the public. Most advanced brain-computer interfaces remain investigational medical devices used only in authorized studies or specific clinical contexts.

What are BCI companies trying to achieve?

Most current BCI projects focus on medical needs rather than general human enhancement.

Their objectives include:

• Restoring communication
• Controlling a computer without physical movement
• Generating speech from neural activity
• Operating robotic limbs
• Restoring aspects of vision
• Monitoring neurological activity
• Supporting movement rehabilitation
• Treating neurological disorders
• Increasing independence for people with paralysis

 

Some non-invasive companies are also exploring research, wellness, accessibility, and consumer applications.

More ambitious ideas about memory enhancement or direct communication between human minds remain largely experimental. The practical development of reliable medical applications is already a major scientific and engineering challenge.

What challenges do BCI companies face?

Building a brain-computer interface requires expertise in neuroscience, surgery, electronics, materials, artificial intelligence, software, and medical regulation.

Surgical safety

Implanted devices must be positioned without causing unacceptable medical risks. Developers are experimenting with surface arrays, flexible materials, robotic insertion, and blood-vessel delivery.

Signal quality

The system must record enough neural information to determine what the user intends. Non-invasive devices are safer but generally collect less detailed signals.

Decoding accuracy

Brain activity is complex and varies between individuals. AI models must learn to distinguish useful signals from noise and adapt to each user.

Long-term stability

Electrodes may move, degrade, or become less effective because of the body’s response to a foreign material. A practical implant needs to operate consistently for years.

Privacy

Brain data is extremely sensitive. Companies need clear policies for consent, ownership, storage, access, and secondary use.

Commercial scalability

A successful laboratory demonstration may still be too expensive or complex for widespread clinical adoption. Companies must make implantation, maintenance, training, and technical support practical.

The role of artificial intelligence in BCI development

Artificial intelligence is essential to modern brain-computer interfaces.

Machine learning models analyze neural recordings and identify patterns associated with intended movements, words, or actions. The models can learn from individual users, improving their performance as they receive more training data.

AI may also help researchers understand neurological conditions, optimize stimulation, and identify meaningful changes in brain activity.

However, artificial intelligence requires reliable context in both human and business applications. A BCI model needs accurate neural data to interpret intention. An enterprise AI agent needs accurate organizational knowledge to interpret a business situation.

This is where Growy plays a distinct role. It gives AI systems the internal context required to work effectively inside a company, just as BCI decoding software gives an external device the context required to interpret neural signals.

What is the future of brain-computer interfaces?

The next stage of BCI development will depend on clinical evidence and long-term reliability.

Companies must demonstrate that their systems remain safe and useful beyond controlled laboratory experiments. Researchers will continue comparing surgical risk, signal quality, bandwidth, durability, and usability.

Different approaches may ultimately serve different purposes.

Intracortical implants could provide detailed control for people with severe paralysis. Surface and endovascular systems may offer a balance between performance and surgical complexity. Non-invasive platforms may become more common in research, accessibility, wellness, and consumer products.

As these physical interfaces evolve, companies will also need better systems for managing the information produced by humans and AI. The future of intelligence technology will therefore involve both individual and collective forms of memory.

Brain-computer interface companies are building connections between people and machines. Growy is building the intelligence layer that connects an organization’s knowledge, employees, tools, and AI agents.

Both developments reflect the same fundamental objective: making information easier to access, understand, and use. For businesses, Growy offers a practical way to achieve that objective today, without implants, by transforming scattered company knowledge into a shared and actionable brain.